Topic metabolic disease

Companies metabolic disease

Biomol GmbH, Germany

Biomol GmbH offers antibodies, enzymes, bioactive lipids, microarrays and reagents for biomedical research. Our focus is on cellular regulation and signal transduction. Together with our partners, we also provide a variety of specialized kits for drug discovery. more

Products metabolic disease

ELISA kits for the measurment of SDF-1/CXCL12

SDF-1α (CXCL12) is a CXC chemokine. The small basic protein (ca. 8 kDa) has no glycosylation site in its sequence. The homology properties of SDF-1α are unique among the chemokines more

Catalogues metabolic disease

Fat Cells, Immune Cells and Metabolic Syndrome

The Importance of the research into Metabolic Syndrome and related diseases is fascinating. Which methods and tools do experts use? more

News metabolic disease

• Increase in cancers and fertility problems may be caused by household chemicals and pharmaceuticals

  Chemicals which disrupt the hormone system – also known as ‘endocrine disrupting chemicals’ (EDCs) – may be behind  significant increases in cancers, diabetes and obesity, falling fertility, and an increased number of neurological development problems in both humans and animals, according to a revie more

• Immune cells found to counter obesity-related diabetes

  For years, researchers have known that obesity, type 2 diabetes and low-level inflammation are linked, but how they are connected has not been well understood. A recent Cornell-led study has found that a type of immune cells - called natural killer T (NKT) cells - is an important part of the puzzle. more

• Midatech and MonoSol Rx Announce Positive Phase 1 Clinical Results for their Novel Transbuccal Oral Insulin Film Product

  Midatech Ltd. and MonoSol Rx LLC announced positive bioavailability and pharmacokinetic results from a first-in-human Phase 1 clinical study of their Midaform™ Insulin PharmFilm product in 27 healthy volunteers. The companies have licensed to their joint venture company, MidaSol Therapeutics LLC, a more

White papers metabolic disease

• Orphan Drugs – An Alternative to the declining Blockbuster Model?
  

  Up until the new millennium, the pharmaceutical industry grew stronger by 11%. However, the blockbuster model is increasingly at risk and the declining growth rates in the industry require a search for new strategies. In this context, orphan drugs are becoming increasingly important more

Publications metabolic disease

• Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies

  Background and purpose:  High levels of glutamic acid decarboxylase (GAD)‐ab were initially described in patients with stiff person syndrome, and have since also been observed in patients with other neurological diseases. Temporal lobe epilepsy (TLE) seems to be specially associated. Our purpose i more

• Prevalence of hepatitis B virus infection among persons with diagnosed diabetes mellitus in the United States, 1999–2010*

  Summary.  The prevalence of hepatitis B virus (HBV) infection among persons with diabetes has not been assessed among the US population, despite increasing reports of HBV transmission in institutional care settings. Using national survey data, we found a 60% higher prevalence of HBV infection amon more

• The Number of X Chromosomes Causes Sex Differences in Adiposity in Mice

  by Xuqi Chen, Rebecca McClusky, Jenny Chen, Simon W. Beaven, Peter Tontonoz, Arthur P. Arnold, Karen Reue Sexual dimorphism in body weight, fat distribution, and metabolic disease has been attributed largely to differential effects of male and female gonadal hormones. Here, we report that more

Market studies metabolic disease

• China Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: 2012 is a very important year for the country as the government look to carry on their achievements following the healthcare reform in 2009. We highlight that the expansion of the National Essential Drug List (NEDL) slated to happen this year will bring strong opportunities for pharmaceuti more

• France Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: Despite concerted progress made on the fiscal consolidation front in the first half of 2011, the French government’s medium-term fiscal targets remain on the optimistic side, particularly given the deteriorating global macroeconomic backdrop and the potential need for state-led capital inj more

• Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report provides comp more

Websites metabolic disease